Magnesium Citrate in Chronic Masticatory Myofascial Pain
CompletedNot applicableNCT07860658
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study examined whether adding an oral magnesium supplement to behavioral counseling reduced pain in adults with chronic jaw muscle pain. Fifty adults were randomly assigned to two groups. One group received magnesium citrate providing 200 mg of elemental magnesium daily for 30 days and behavioral counseling. The other group received behavioral counseling alone. Pain, jaw movement, jaw function, pain-related disability, and anxiety were assessed before treatment and at 1 and 3 months. The main outcome was jaw muscle pain intensity at 3 months. Adverse events were also recorded. The study was completed before registration.
Study details
- Official title
- Oral Magnesium Citrate as an Adjunct to Behavioral Counseling for Chronic Masticatory Myofascial Pain: An Assessor-Blinded Randomized Controlled Trial
- Conditions
- Chronic Masticatory Myofascial Pain
- Interventions
- Dietary supplement: Magnesium citrate
- Behavioral: Behavioral counseling
- Sponsor
- Muhammet Yasin Pektaş
- Organization
- Kutahya Health Sciences University
- Start date
- 2023-07-01
- Primary completion
- 2024-07-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18 to 65 years. * DC/TMD Axis I diagnosis of myalgia/myofascial pain. * Pain persisting or recurring for at least 3 months. * Palpable trigger points in the masseter or temporalis muscles. Exclusion Criteria: * Other TMD subtypes. * Systemic inflammatory or neurological disorders. * Current magnesium supplementation. * Contraindications to magnesium. * Renal impairment. * Pregnancy. * Severe psychiatric disorders. * Ongoing TMD-related litigation. * Inability to complete Turkish questionnaires.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07860658